What’s the current market cap for Moderna stock?

Moderna (MRNA) has a market cap of $19B as of May 23, 2026.

What is the P/E ratio for Moderna stock?

The price to earnings (P/E) ratio for Moderna (MRNA) stock is 0 as of May 23, 2026.

Does Moderna stock pay dividends?

No, Moderna (MRNA) stock does not pay dividends to its shareholders as of May 23, 2026.

When is the next Moderna dividend payment date?

Moderna (MRNA) stock does not pay dividends to its shareholders.

What is the beta indicator for Moderna?

Moderna (MRNA) has a beta rating of 1.34. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy Moderna stock | $MRNA Share Price

13:30

15:10

16:45

18:25

20:00

About Moderna

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

Ticker

$MRNA

Sector

Health

Primary listing

NASDAQ

Employees

4,700

Headquarters

Cambridge, United States

Website

www.modernatx.com

Moderna Metrics

BasicAdvanced

$19bn

-$8.16

1.34

What the Analysts think about Moderna

Analyst ratings (Buy, Hold, Sell) for Moderna stock.

Bulls say / Bears say

Moderna’s Q1 revenue more than tripled to $389 million, with nearly 80% of COVID vaccine sales coming from outside the U.S., surpassing forecasts and supporting its full-year growth guidance of up to 10%.

The European Commission approved mCombriax and mNexspike, increasing Moderna’s marketed vaccine products in the EU to five and diversifying revenue beyond monovalent COVID offerings.

Intismeran follow-up data showed a 49% reduction in recurrence or death in melanoma patients over five years, and a Phase 3 trial began in non-small cell lung cancer, highlighting progress and promise in Moderna’s oncology pipeline.

The FDA’s refusal to file Moderna’s mRNA-1010 seasonal influenza vaccine application in February 2026 delays the U.S. launch of its first mRNA flu shot and underlines ongoing regulatory obstacles.

Moderna will make a $950 million upfront payment (up to $2.25 billion total) to settle patent litigation with Arbutus/Genevant, resulting in major cash outflows and a related Q1 charge.

Management forecasted Q2 revenue of only $50 million–$100 million, which is below analyst expectations and reflects near-term sales volatility as legacy respiratory programs conclude.

Data summarised monthly by Lightyear AI. Last updated on 19 May 2026.

Moderna Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

Moderna Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $MRNA

Capital at risk

Market closed

Upcoming events

No upcoming events

Bulls say / Bears say

The European Commission approved mCombriax and mNexspike, increasing Moderna’s marketed vaccine products in the EU to five and diversifying revenue beyond monovalent COVID offerings.

Moderna will make a $950 million upfront payment (up to $2.25 billion total) to settle patent litigation with Arbutus/Genevant, resulting in major cash outflows and a related Q1 charge.

Management forecasted Q2 revenue of only $50 million–$100 million, which is below analyst expectations and reflects near-term sales volatility as legacy respiratory programs conclude.

Data summarised monthly by Lightyear AI. Last updated on 19 May 2026.